艾皮克萨班作为二次预防剂 专利孔卵巢 - 相关中风
Rebecca M Khaimova1, Yuliana Toderika2,3, Justin Ramnarain1
1Northwell Health, New Hyde Park, NY, USA.
Journal of pharmacy practice
|September 24, 2024
概括
本案例报告详细介绍了由于难以管理的抗凝药和其他因素,将患者从华法林转换为阿皮克萨班. 切换到阿皮克萨班是成功的,改善了患者的满意度,并保持了治疗性抗凝剂,没有不良事件.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
背景情况:
- 一名患有中风病史的患者,其次是 patent foramen ovale (PFO) 和心房动 (AF),正在接受华法林治疗.
- 患者经历了不稳定的国际正常化比率 (INR) 水平,表明非最佳的抗凝血.
- 挑战包括痛苦的埃诺沙巴林注射,不一致的维生素K摄入量和功能波动.
研究的目的:
- 在需要抗凝剂预防的患者中,描述从华法林成功过渡到阿皮克萨班.
- 要突出在患有PFO相关中风和AF的患者中抗凝血的管理.
主要方法:
- 一家由药剂师领导的抗凝药诊所监测了患者的INR.
- 他们共同决定从华法林转换为每天两次2.5毫克的阿皮克萨班.
- 在切换后,对患者的功能和临床状况进行了监测.
主要成果:
- 患者很好地忍受了切换到阿皮克萨班的情况,报告了更高的满意度.
- 在12个月后没有发现出血的迹象或症状,新的脑血管事故 (CVA) 或静脉血栓塞栓症 (VTE) 事件.
- 由于功能改善,阿皮克萨班剂量增加到每天两次5毫克.
结论:
- 从华法林转换为阿皮克萨班可以在特定患者中是一种安全有效的策略.
- 阿皮克萨班为具有挑战性抗凝管理的患者提供了可行的替代方案.
- 这一案例证明了在患有PFO相关中风和AF的患者中成功进行抗凝管理.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
496
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
496
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
649
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
649
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K